Profile data is unavailable for this security.
About the company
Everest Medicines Ltd is a biopharmaceutical company primarily engaged in the discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines. The Company has built a product pipeline across renal, anti-infective, and autoimmune diseases. The Company’s products portfolio includes Nefecon (TARPEYO) using in the renal therapeutic area, XERAVA (eravacycline) using in the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant isolates and other products. The Company conducts its business in the domestic and overseas markets.
- Revenue in HKD (TTM)962.76m
- Net income in HKD-745.02m
- Incorporated2017
- Employees722.00
- LocationEverest Medicines Ltd16/F., CITIC Pacific Plaza,1168 West Nanjing Road, JingAn DistrictSHANGHAI 200041ChinaCHN
- Websitehttps://www.everestmedicines.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SSY Group Ltd | 4.58bn | 658.92m | 8.73bn | 5.70k | 13.50 | 1.22 | 7.76 | 1.90 | 0.223 | 0.223 | 1.55 | 2.46 | 0.3616 | 2.27 | 2.11 | 751,065.60 | 5.27 | 9.41 | 6.34 | 12.43 | 42.68 | 56.47 | 14.58 | 17.65 | 2.40 | 14.91 | 0.346 | 42.91 | -10.67 | 4.49 | -19.53 | -1.36 | -8.36 | 9.73 |
| Hbm Holdings Ltd | 904.62m | 571.25m | 10.25bn | 210.00 | 15.92 | 4.23 | 17.14 | 11.33 | 0.7407 | 0.7407 | 1.14 | 2.78 | 0.3856 | 6.32 | 32.64 | 5,798,829.00 | 24.77 | -42.87 | 30.77 | -53.24 | 92.95 | 96.12 | 64.25 | -292.58 | 6.02 | 28.63 | 0.1857 | -- | -57.43 | 47.71 | -87.81 | -- | -55.31 | -- |
| China Traditional Chinese Med Hldg CoLtd | 17.63bn | -299.51m | 10.27bn | 15.58k | -- | 0.4388 | 11.31 | 0.5827 | -0.0595 | -0.0595 | 3.50 | 4.65 | 0.4326 | 1.59 | 1.71 | 1,052,279.00 | -0.93 | 3.48 | -1.42 | 5.24 | 47.66 | 54.69 | -2.15 | 7.39 | 1.51 | 9.55 | 0.1333 | 21.27 | -8.90 | 2.89 | -95.79 | -49.14 | -15.28 | -48.82 |
| Luye Pharma Group Ltd | 6.98bn | 448.92m | 10.67bn | 5.12k | 22.37 | 0.6044 | 6.67 | 1.53 | 0.1193 | 0.1193 | 1.85 | 4.42 | 0.2083 | 2.42 | 2.37 | 1,354,499.00 | 1.91 | 1.98 | 3.26 | 3.16 | 66.85 | 68.37 | 9.15 | 8.04 | 1.24 | 2.35 | 0.4227 | 0.00 | -1.33 | -0.9503 | -11.40 | -19.50 | -10.95 | -- |
| Fujian Haixi Pharmaceuticals Co Ltd | -100.00bn | -100.00bn | 10.70bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 47.39 | -- | 15.86 | -- | -- | -- |
| Guangzhou Innogen Pharmaceutl Grp Co Ltd | -100.00bn | -100.00bn | 12.64bn | 105.00 | -- | 14.88 | -- | -- | -- | -- | -- | 1.84 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.39 | -- | 0.0769 | -- | -- | -- | 76.18 | -- | -- | -- |
| Everest Medicines Ltd | 962.76m | -745.02m | 13.52bn | 722.00 | -- | 2.82 | -- | 14.04 | -2.31 | -2.31 | 2.98 | 13.55 | 0.1684 | 13.97 | 3.04 | 1,447,760.00 | -13.03 | -29.28 | -14.21 | -31.67 | 69.92 | -- | -77.38 | -1,040.86 | 5.43 | -- | 0.1577 | -- | 461.16 | -- | -23.32 | -- | 16.96 | -- |
| CF PharmTech Inc | 683.02m | 31.39m | 14.53bn | 574.00 | 463.04 | 13.40 | 141.62 | 21.27 | 0.0762 | 0.0762 | 1.66 | 2.63 | -- | -- | -- | -- | -- | -- | -- | -- | 80.18 | -- | 4.60 | -- | 1.89 | -- | 0.076 | -- | 9.23 | -- | -33.53 | -- | -- | -- |
| Sihuan Pharmaceutical Holdings Group Ltd | 2.37bn | -91.19m | 15.00bn | 2.77k | -- | 3.04 | -- | 6.32 | -0.0098 | -0.0098 | 0.2571 | 0.5394 | 0.1894 | 1.49 | 3.86 | 889,501.40 | -3.05 | -3.60 | -5.01 | -5.05 | 66.29 | 73.13 | -16.08 | -19.74 | 1.61 | -1.36 | 0.1606 | -- | 2.18 | -7.96 | -301.10 | -- | -20.58 | 3.60 |
| Consun Pharmaceutical Group Ltd | 3.70bn | 1.14bn | 15.15bn | 3.07k | 13.54 | 3.12 | 12.44 | 4.10 | 1.33 | 1.33 | 4.31 | 5.77 | 0.5642 | 2.35 | 12.33 | 1,167,866.00 | 17.60 | 14.71 | 24.67 | 22.82 | 76.62 | 75.04 | 31.20 | 29.56 | 3.32 | -- | 0.0517 | 40.93 | 14.56 | 11.42 | 16.05 | 62.72 | -9.54 | 25.83 |
| Zai Lab Ltd | 3.45bn | -1.62bn | 16.38bn | 1.87k | -- | 2.70 | -- | 4.74 | -1.52 | -1.52 | 3.21 | 5.37 | 0.4119 | 3.19 | 6.53 | -- | -19.29 | -33.80 | -27.61 | -39.12 | 61.52 | 64.07 | -46.83 | -186.77 | 2.68 | -- | 0.2108 | -- | 49.59 | 98.38 | 23.17 | -- | 32.19 | -- |
| Ascletis Pharma Inc | 2.67m | -292.43m | 17.87bn | 208.00 | -- | 7.68 | -- | 6,683.74 | -0.2989 | -0.2989 | 0.0027 | 2.19 | 0.0011 | 0.2668 | 11.59 | 11,573.89 | -12.10 | -8.46 | -12.73 | -8.80 | 36.21 | 7.91 | -10,937.78 | -522.12 | 14.53 | -- | 0.0023 | -- | -97.73 | -62.52 | -107.95 | -- | -40.26 | -- |
| Vigonvita Life Sciences Co Ltd | -100.00bn | -100.00bn | 18.10bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -94.07 | -- | -1,848.73 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Everest Medicines Ltd's reporting currency: Hong Kong Dollar HKD
9.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 07 Jan 2026 | 10.43m | 2.95% |
| Ping An Fund Management Co., Ltd.as of 30 Jun 2025 | 6.97m | 1.97% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 3.87m | 1.10% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 3.09m | 0.88% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 2.39m | 0.68% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 2.10m | 0.59% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 1.51m | 0.43% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 1.12m | 0.32% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2025 | 1.04m | 0.29% |
| BlackRock Advisors (UK) Ltd.as of 09 Jan 2026 | 981.50k | 0.28% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
